These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32912949)

  • 1. What are the cost-savings and health benefits of improving detection and management for six high cardiovascular risk conditions in England? An economic evaluation.
    Thomas C; Brennan A; Goka E; Squires HY; Brenner G; Bagguley D; Buckley Woods H; Gillett M; Leaviss J; Clowes M; Heathcote L; Cooper K; Breeze P
    BMJ Open; 2020 Sep; 10(9):e037486. PubMed ID: 32912949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the potential return on investment of the proposed UK NHS diabetes prevention programme in different population subgroups: an economic evaluation.
    Thomas C; Sadler S; Breeze P; Squires H; Gillett M; Brennan A
    BMJ Open; 2017 Aug; 7(8):e014953. PubMed ID: 28827235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
    Whitfield MD; Gillett M; Holmes M; Ogden E
    Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Including Costs and Outcomes of Dementia in a Health Economic Model to Evaluate Lifestyle Interventions to Prevent Diabetes and Cardiovascular Disease.
    Breeze P; Thomas C; Thokala P; Lafortune L; Brayne C; Brennan A
    Med Decis Making; 2020 Oct; 40(7):912-923. PubMed ID: 32951510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits of population-level interventions for dementia risk factors: an economic modelling study for England.
    Mukadam N; Anderson R; Walsh S; Wittenberg R; Knapp M; Brayne C; Livingston G
    Lancet Healthy Longev; 2024 Sep; 5(9):100611. PubMed ID: 39096915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The current and potential health benefits of the National Health Service Health Check cardiovascular disease prevention programme in England: A microsimulation study.
    Mytton OT; Jackson C; Steinacher A; Goodman A; Langenberg C; Griffin S; Wareham N; Woodcock J
    PLoS Med; 2018 Mar; 15(3):e1002517. PubMed ID: 29509767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and cost-effectiveness of interventions that cause weight loss and reduce the risk of cardiovascular disease.
    Zomer E; Leach R; Trimmer C; Lobstein T; Morris S; James WP; Finer N
    Diabetes Obes Metab; 2017 Jan; 19(1):118-124. PubMed ID: 27649286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gaps in antihypertensive and statin treatments and benefits of optimisation: a modelling study in a 1 million ethnically diverse urban population in UK.
    Wu R; Rison SCG; Raisi-Estabragh Z; Dostal I; Carvalho C; Robson J; Mihaylova B
    BMJ Open; 2021 Dec; 11(12):e052884. PubMed ID: 35536740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health Impact and Cost-Effectiveness of Achieving the National Salt and Sugar Reduction Initiative Voluntary Sugar Reduction Targets in the United States: A Microsimulation Study.
    Shangguan S; Mozaffarian D; Sy S; Lee Y; Liu J; Wilde PE; Sharkey AL; Dowling EA; Marklund M; Abrahams-Gessel S; Gaziano TA; Micha R
    Circulation; 2021 Oct; 144(17):1362-1376. PubMed ID: 34445886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What will the cardiovascular disease slowdown cost? Modelling the impact of CVD trends on dementia, disability, and economic costs in England and Wales from 2020-2029.
    Collins B; Bandosz P; Guzman-Castillo M; Pearson-Stuttard J; Stoye G; McCauley J; Ahmadi-Abhari S; Araghi M; Shipley MJ; Capewell S; French E; Brunner EJ; O'Flaherty M
    PLoS One; 2022; 17(6):e0268766. PubMed ID: 35767575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study.
    Barton P; Andronis L; Briggs A; McPherson K; Capewell S
    BMJ; 2011 Jul; 343():d4044. PubMed ID: 21798967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Future cost-effectiveness and equity of the NHS Health Check cardiovascular disease prevention programme: Microsimulation modelling using data from Liverpool, UK.
    Kypridemos C; Collins B; McHale P; Bromley H; Parvulescu P; Capewell S; O'Flaherty M
    PLoS Med; 2018 May; 15(5):e1002573. PubMed ID: 29813056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review and economic evaluation of exercise referral schemes in primary care: a short report.
    Campbell F; Holmes M; Everson-Hock E; Davis S; Buckley Woods H; Anokye N; Tappenden P; Kaltenthaler E
    Health Technol Assess; 2015 Jul; 19(60):1-110. PubMed ID: 26222987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health Benefits and Cost-Effectiveness of Asymptomatic Screening for Hypertension and High Cholesterol and Aspirin Counseling for Primary Prevention.
    Dehmer SP; Maciosek MV; LaFrance AB; Flottemesch TJ
    Ann Fam Med; 2017 Jan; 15(1):23-36. PubMed ID: 28376458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which elderly patients should be considered for anti-hypertensive treatment? An evidence-based approach.
    Jackson R
    J Hum Hypertens; 1998 Sep; 12(9):607-13. PubMed ID: 9783489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating the health and economic effects of the proposed US Food and Drug Administration voluntary sodium reformulation: Microsimulation cost-effectiveness analysis.
    Pearson-Stuttard J; Kypridemos C; Collins B; Mozaffarian D; Huang Y; Bandosz P; Capewell S; Whitsel L; Wilde P; O'Flaherty M; Micha R
    PLoS Med; 2018 Apr; 15(4):e1002551. PubMed ID: 29634725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of a statewide public health intervention to reduce cardiovascular disease risk.
    Smith L; Atherly A; Campbell J; Flattery N; Coronel S; Krantz M
    BMC Public Health; 2019 Sep; 19(1):1234. PubMed ID: 31492118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare Expenditure and Productivity Cost Savings from Reductions in Cardiovascular Disease and Type 2 Diabetes Associated with Increased Intake of Cereal Fibre among Australian Adults: A Cost of Illness Analysis.
    Fayet-Moore F; George A; Cassettari T; Yulin L; Tuck K; Pezzullo L
    Nutrients; 2018 Jan; 10(1):. PubMed ID: 29301298
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.